time in a victory against New Zealand. In the final, Great Britain defeated Australia to bring Wiggins his eighth Olympic medal, and his fifth gold. Subsequently, Wiggins announced his plan to retire after the Six Days of Ghent in November. He plans to expand his activities in supporting and running Team Wiggins, including an aim to create a women's team. In his penultimate racing event, the Six Days of London, Wiggins placed second overall with Cavendish, before the pair won his final event, the Six Days of Ghent. After the event, Wiggins confirmed that this had been his last race as a team with Cavendish, but that he may go back on his decision to retire, in the right circumstances. However, on 28 December 2016 he announced that he was retiring from professional cycling saying "2016 is the end of the road for this chapter, onwards and upwards, 'feet on the ground, head in the clouds' kids from Kilburn don't win Olympic Golds and Tour de Frances! They do now." Controversy around therapeutic use exemptions The leaking of his personal medical history by a group of hackers called the Fancy Bear, in September 2016, raised questions about Wiggins's use of therapeutic use exemptions (TUEs), which allow athletes with certified medical conditions to take banned substances so as to allow them to compete with healthy athletes. The leaked files show that he received six TUEs during his career for substances which are otherwise banned by WADA. In 2008, he was granted TUEs for salbutamol (which has since been legalised), formoterol and budesonide to treat asthma. Wiggins later received three intramuscular injections of the drug triamcinolone, a powerful corticosteroid. Triamcinolone is a banned substance because it allows riders to lose weight while maintaining power. The injections were administered to treat hayfever shortly before the 2011 and 2012 Tour de France races, and the 2013 Giro d'Italia. Dr. Jeroen Swart, the South Africa-based exercise physiologist who oversaw Chris Froome's independent physiological testing, has suggested that the 2012 injection of triamcinolone ahead of Wiggins's historic Tour de France victory may have been administered as a preventive measure, rather than to treat existing symptoms, even though it is not a first-line therapy. Whilst the use of banned performance-enhancing substances under TUEs is permitted by the sporting authorities provided the exemption was granted in terms of the WADA rules, questions have been raised about the in-competition